HUP0002395A3 - Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors - Google Patents

Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors

Info

Publication number
HUP0002395A3
HUP0002395A3 HU0002395A HUP0002395A HUP0002395A3 HU P0002395 A3 HUP0002395 A3 HU P0002395A3 HU 0002395 A HU0002395 A HU 0002395A HU P0002395 A HUP0002395 A HU P0002395A HU P0002395 A3 HUP0002395 A3 HU P0002395A3
Authority
HU
Hungary
Prior art keywords
benzothiepines
hmg
pharmaceutical compositions
compositions containing
bile acid
Prior art date
Application number
HU0002395A
Other languages
Hungarian (hu)
Original Assignee
G D Searle & Co Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002395(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G D Searle & Co Chicago filed Critical G D Searle & Co Chicago
Publication of HUP0002395A2 publication Critical patent/HUP0002395A2/en
Publication of HUP0002395A3 publication Critical patent/HUP0002395A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
HU0002395A 1997-03-11 1998-03-10 Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors HUP0002395A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4066097P 1997-03-11 1997-03-11
PCT/US1998/003792 WO1998040375A2 (en) 1997-03-11 1998-03-10 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Publications (2)

Publication Number Publication Date
HUP0002395A2 HUP0002395A2 (en) 2001-05-28
HUP0002395A3 true HUP0002395A3 (en) 2002-12-28

Family

ID=21912237

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002395A HUP0002395A3 (en) 1997-03-11 1998-03-10 Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors

Country Status (16)

Country Link
EP (1) EP0971744A2 (en)
JP (1) JP2002500628A (en)
CN (1) CN1255864A (en)
AU (1) AU730024C (en)
BG (1) BG103793A (en)
BR (1) BR9808013A (en)
CA (1) CA2283575A1 (en)
HU (1) HUP0002395A3 (en)
IL (1) IL131872A0 (en)
MX (1) MXPA99008417A (en)
NO (1) NO994390L (en)
NZ (1) NZ337830A (en)
PL (1) PL336415A1 (en)
RU (1) RU2247579C2 (en)
SK (1) SK125099A3 (en)
WO (1) WO1998040375A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU2003241629B2 (en) * 1999-04-19 2005-06-16 Astrazeneca Ab An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (en) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002051396A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
MY131995A (en) 2001-09-08 2007-09-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
JP2005516941A (en) 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド Chalcone derivatives and their use for treating diseases
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
AU2003257578B2 (en) * 2002-08-28 2009-01-22 Asahi Kasei Pharma Corporation Novel quaternary ammonium compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP4711953B2 (en) 2004-02-27 2011-06-29 旭化成ファーマ株式会社 Novel benzothiazepine and benzothiepine compounds
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
SG190433A1 (en) 2010-11-08 2013-06-28 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
BR112013010157B1 (en) 2010-11-08 2020-02-04 Albireo Ab ibat inhibitors, their uses, and pharmaceutical composition and combinations
SG10201406155QA (en) 2011-10-28 2014-11-27 Lumena Pharmaceuticals Inc Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
US20140243281A1 (en) 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
JP2016514684A (en) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー Bile acid recirculation inhibitors for the treatment of primary sclerosing cholangitis and inflammatory bowel disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
CN106794188B (en) * 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 Polymeric bile acid derivatives inhibit hepatitis B and delta virus and NTCP trafficking
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
JP6954926B2 (en) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ Oral cholestyramine preparation and its use
JP6954927B2 (en) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ Oral cholestyramine preparation and its use
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN110996915B (en) 2017-08-09 2023-10-03 阿尔比里奥公司 Cholestyramine pellet, oral cholestyramine preparation and application thereof
JP2020530448A (en) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ Cholestyramine granules, oral cholestyramine preparations, and their use
JP7391048B2 (en) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013839A (en) 2018-06-20 2021-03-25 Albireo Ab Pharmaceutical formulation of odevixibat.
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
UA127911C2 (en) 2019-02-06 2024-02-07 Альбірео Аб Benzothiadiazepine compounds and their use as bile acid modulators
ES2955799T3 (en) 2019-02-06 2023-12-07 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021009625A (en) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Methods for increasing growth in pediatric subjects having cholestatic liver disease.
TW202134220A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
AR120683A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID
DK4069360T3 (en) 2019-12-04 2024-02-26 Albireo Ab BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
AR120679A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AR120674A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
JP2023504643A (en) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
CN114786772B (en) 2019-12-04 2024-04-09 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
EP4188541A1 (en) 2020-08-03 2023-06-07 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN112274648B (en) * 2020-11-23 2022-10-14 郑州大学 Preparation method of cholesterol oxidase modified hybrid metal organic framework tumor targeting nano preparation
BR112023010799A2 (en) 2020-12-04 2023-10-03 Albireo Ab BENZOTIA(DI)AZEPINE COMPOUNDS AND THEIR USES AS BILLARY ACID MODULATORS
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024044183A1 (en) * 2022-08-22 2024-02-29 Enanta Pharmaceuticals, Inc. Fused heterobicyclic antiviral agents

Also Published As

Publication number Publication date
AU730024C (en) 2004-08-05
BG103793A (en) 2000-07-31
AU730024B2 (en) 2001-02-22
CN1255864A (en) 2000-06-07
NO994390D0 (en) 1999-09-10
NO994390L (en) 1999-11-04
NZ337830A (en) 2001-07-27
JP2002500628A (en) 2002-01-08
EP0971744A2 (en) 2000-01-19
HUP0002395A2 (en) 2001-05-28
AU6440898A (en) 1998-09-29
RU2247579C2 (en) 2005-03-10
PL336415A1 (en) 2000-06-19
MXPA99008417A (en) 2005-02-03
WO1998040375A3 (en) 1998-12-03
CA2283575A1 (en) 1998-09-17
SK125099A3 (en) 2001-02-12
IL131872A0 (en) 2001-03-19
BR9808013A (en) 2001-09-25
WO1998040375A2 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
HUP0002395A3 (en) Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
HUP0301087A3 (en) Oral pharmaceutical composition comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
HUP0105409A3 (en) 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake, use thereof and pharmaceutical compositions containing them
PL346324A1 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
HUP9903047A3 (en) Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
PL348609A1 (en) Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
HUP0202469A3 (en) Cell adhesion inhibitor compound and pharmaceutical composition containing thereof
HUP0104793A2 (en) Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
HUP0000979A3 (en) Pharmaceutical compositions containing fk-506 and derivatives thereof
HUP0002510A3 (en) Tetrazole derivatives and pharmaceutical compositions containing them
HUP0202938A3 (en) N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them
IL130150A0 (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
HUP0002951A3 (en) Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
HUP0003330A3 (en) Pharmaceutical compositions containing tizoxanide and nitazoxanide
AU3953197A (en) Catechol amino acid derivatives and pharmaceutical compositions containing them
HUP0001061A3 (en) Naphthylsulfonic acid derivatives and pharmaceutical compositions containing them
HUP0201880A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
SI1091953T1 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
HU9701093D0 (en) Pharmaceutical composition containing huminic acid
HUP0002035A3 (en) Sulfonamidoalkyl-carbonyl-(carbomoyl-oxy)phenylalanine derivatives and pharmaceutical compositions containing them
IL118248A0 (en) Hydroxamic acid and amino-carboxylate compounds and pharmaceutical compositions containing them
HUP9903695A3 (en) Oxazolyl- and pyridylethoxyphenyl propionic acid derivatives and pharmaceutical compositions containing them
HUP9903370A3 (en) Beta-sulfonamido hydroxamic acids and pharmaceutical compositions containing them
HUP9902470A3 (en) Biphenylsulfonylamino alkylcarboxylic acid derivatives and pharmaceutical compositions containing them